Company Filing History:
Years Active: 1998
Title: The Innovative Contributions of Jean S. Marshall in Allergy Treatment
Introduction
Jean S. Marshall, based in Etobicoke, Canada, is a notable inventor recognized for his significant contributions to the field of immunology, specifically in the treatment of type I hypersensitivity. With one patent to his name, his innovative approach has the potential to greatly impact how allergic reactions are managed.
Latest Patents
Marshall’s patent, titled "Methods of treating type I hypersensitivity using monophosphoryl lipid A," describes a groundbreaking methodology for treating immunoglobulin E (IgE)-dependent hypersensitivity. The patent reveals how the administration of monophosphoryl lipid A (MLA) or its variant, 3-deacylated monophosphoryl lipid A (3D-MLA), can significantly reduce allergen-specific IgE levels while enhancing IgG antibody levels in patients. This treatment can be employed alone or in conjunction with allergens, making it a flexible option for desensitization regimens or prophylactic vaccines aimed at preventing hypersensitivity reactions.
Career Highlights
Jean S. Marshall is currently affiliated with Ribi Immunochem Research, Inc., a company dedicated to advancing research in immunotherapy and allergy treatments. His work at Ribi involves collaborating on innovative solutions to combat allergic responses, reflecting his commitment to improving patient health through scientific advancements.
Collaborations
Throughout his career, Marshall has worked alongside esteemed colleagues such as Jerry Dolovich and J. Terry Ulrich. Their collaborative efforts have contributed to significant progress in the understanding and treatment of hypersensitivity disorders, showcasing the power of teamwork in the field of research and innovation.
Conclusion
Jean S. Marshall stands out as an influential figure in the realm of allergy research. His patent for treating type I hypersensitivity exemplifies his dedication to developing effective therapies that can alleviate the burden of allergies for many. As he continues his work at Ribi Immunochem Research, Inc., the scientific community eagerly anticipates further advancements stemming from his innovative ideas.